CRAFITY score as a predictive marker for refractoriness to atezolizumab plus bevacizumab therapy in hepatocellular carcinoma: a multicenter retrospective study.
Masayuki UenoHaruhiko TakedaAtsushi TakaiHiroki MorimuraNorihiro NishijimaSatoru IwamotoShunsuke OkuyamaMakoto UmedaTakeshi SetaAtsuyuki IkedaTomoyuki GotoShin'ichi MiyamotoTakahisa KayaharaYoshito UenoyamaKazuyoshi MatsumuraShigeharu NakanoMasako MishimaTadashi InuzukaYuji EsoKen TakahashiHiroyuki MarusawaYukio OsakiEtsuro HatanoHiroshi SenoPublished in: Journal of gastroenterology (2024)
Approximately one-third of patients were refractory to first-line Atezo/Bev therapy. The CRAFITY score demonstrated superior performance in predicting refractoriness.